• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us
Sleep Diagnosis and Therapy

Sleep Diagnosis and Therapy

Official Publication of the American Sleep and Breathing Academy

SomnoMed Continues with Sales Growth and New Sales Records in Latest Quarter

May 4, 2012 by admin

FRISCO, Texas, SomnoMed Limited (ASX: SOM) announced today its results for the third quarter to March 2012. Unit sales reached a new record with 7,903 units, 25% higher than in the same quarter in the previous year, when sales reached 6,346 units. Third quarter sales were ahead of Q2 sales with increased sales in all regions (US, APAC andEurope) in Q3. Global unit sales for the nine months are just over 22,000 units.

Revenue numbers for the March quarter of $3.8 million were 26% more than the same period last year. Total revenue growth for the full 9 months is 18% (26% with constant exchange rates).

SomnoMed’s CEO Mr Ralf Barschow commented, “New record sales were achieved in all regions in Q3 and trends are encouraging for the remainder of the financial year.”

All regions generated operating profits well ahead of the corresponding period in the prior year. The ongoing investment in manufacturing, operations and logistics during the year has again allowed SomnoMed to increase the gross margin of the business to 69% from 67% in the March quarter of 2011.”

“The recent announcement that SomnoMed’s MATRx system has now received FDA clearance allows us to put the proof of individual treatment effectiveness in the forefront of our medical drive and strategic positioning in the industry in anticipation of the Sleep Congress 2012 to be held in June in Boston, USA,” commented Mr Barschow.

The cash use for the quarter was $170,000, including cash payments of $371,000 made in connection to the completion of the acquisition of SomnoMed’s share in the Dutch company and associated transaction costs. SomnoMed had a cash balance of$3.1 million at the end of Q3.

Visit: SomnoMed Website

Source: PRnewswire

Related: OSA Sufferers Finding Comfort in the Dental Office


Filed Under: Blog

Primary Sidebar

More to See

Xywav Oral Solution for Idiopathic Hypersomnia

February 16, 2022 By Alan Hickey

New Insomnia Drug Improves Sleep Outcomes for Adults

February 10, 2022 By Alan Hickey

Tags

apnea CPAP Health Home Sleep Home Sleep Testing insomnia narcolepsy obstructive sleep apnea Sleep sleep apnea sleep apnea symptoms sleep apnea syndrome sleep apnea treatment sleep appliances sleep buisness Sleep Business sleep center Sleep Centers sleep community sleep diagnosis sleep diagnostic sleep diagnostics sleep disease sleep disorder sleep disorder center sleep disordered breathing sleep disorders sleep heart health sleep industry sleeping Sleep Lab sleep labs sleep management sleep medicine sleep monitor sleep physicians sleep problems sleep studies sleep study sleep technologist sleep test sleep testing Technology therapy Treatment

Footer

About SleepDT

SleepDT Sleep Diagnosis and Therapy is a clinical Journal for allied Sleep Professionals, Neurologists, Psychiatrists, Pulmonologists, Primary Care Physicians, and other medical specialists. We also advocate on behalf of patient care in the field of Sleep Medicine

Recent

  • Sleep Hygiene: Which Bedroom Colors to Avoid and which Promote Good Sleep??
  • Xywav Oral Solution for Idiopathic Hypersomnia
  • New Insomnia Drug Improves Sleep Outcomes for Adults
  • Mark Cuban Billionaire Entrepreneur and Television Personality Launches Online Pharmacy for Generic Drugs
  • Americans Say They’re Sleep-Deprived After the Super Bowl

NAVIGATION

  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us

Copyright © 2022 · Sleep Diagnosis and Therapy